The association of VEGF rs833061 and rs2010963 polymorphisms with susceptibility to colorectal cancer in an Iranian population

Bakhshian-Dehkordi, Ehsan; Safaei, Mohsen; Fattahi, Soheila; Faghani, Mostafa; Deris, Fatemeh; Chaleshtori, Morteza Hashemzadeh

doi:10.1016/j.canep.2021.102041

Cited by 7 publications

(5 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…54 studies comprising 60 reports were enrolled initially, published literature [19–68] and gray literature. [69–72] We included 46 English-language articles and 8 Chinese-language articles.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The relationship between VEGF-460(T>C) polymorphism and cancer risk: A systematic review and meta-analysis based on 46 reports

et al. 2023

View full text Add to dashboard Cite

Background: Extensive studies on the link between single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) and various malignancy risks produced conflicting results, notably for VEGF-460(T/C). To evaluate this correlation more comprehensively and accurately, we perform a meta-analysis. Methods: Through retrieving 5 databases (Web of Science (WoS), Embase, Pubmed, Wanfang database (Wangfang), and China National Knowledge Infrastructure (CNKI)) and applying hand search, citation search, and gray literature search, 44 papers included 46 reports were enrolled. To evaluate the relationship between VEGF-460 and cancer risk, we pooled odds ratios (ORs) and 95% confidence intervals (CIs). Results: Our results indicated that the VEGF-460 polymorphism is not related to malignancy susceptibility (dominant model, OR = 0.98, 95% CI = 0.87–1.09; recessive model, OR = 0.95, 95% CI = 0.82–1.10; heterozygous model, OR = 0.99, 95% CI = 0.90–1.10; homozygous model, OR = 0.92, 95% CI = 0.76–1.10; additive model, OR = 0.98, 95% CI = 0.90–1.07). While, in subgroup analysis, this SNP may reduce the risk of hepatocellular carcinoma. Conclusion: this meta-analysis indicated that VEGF-460 was irrelevant to overall malignancy risk, but it might be a protective factor for hepatocellular carcinoma.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Numerous institutions have performed extensive studies to demonstrate the relationship between SNPs in VEGF and cancer, especially for VEGF-460(T/C). [19–78] However, different and even contradictory results were obtained. Several investigators have conducted meta-analyses to evaluate this link comprehensively.…”

Section: Introductionmentioning

confidence: 99%

The relationship between VEGF-460(T>C) polymorphism and cancer risk: A systematic review and meta-analysis based on 46 reports

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In Iran, VEGF gene polymorphism rs833061T/C was reported to be associated with the risk of colorectal cancer. TG genotype holds a higher risk compared to TT and GG genotypes [41]. Furthermore, in Iran, VEGF gene polymorphism +936C>T acted as a protective factor for colorectal cancer, particularly T allele and TT genotype [42].…”

Section: Discussionmentioning

confidence: 99%

Association between VEGF Gene Polymorphism -634G>C and Risk of Colorectal Cancer

Tambunan

Siregar

Syam

2022

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Genetic and environmental factors play an important role in the pathogenesis of colorectal cancer. Angiogenesis is a central process in carcinogenesis and is affected by vascular endothelial growth factor (VEGF). Several genetic variations, such as polymorphism, may alter VEGF expression and influence the risk of colorectal cancer. AIM: The objective of this study was to determine the association between VEGF gene polymorphism -634G>C and risk of colorectal cancer. METHODS: A cross-sectional study was conducted at Haji Adam Malik general hospital and its sister hospitals. Subjects were obtained by consecutive sampling. Inclusion criteria for case and control groups were patients with colorectal cancer and healthy subject, respectively, aged 18 years or older and willing to participate in the study. Exclusion criteria were patients with systemic comorbidities or malignancies in other organs. Each subject undergoes an interview, colonoscopy, biopsy, serum VEGF level measurement, and VEGF polymorphism -634G>C evaluation. RESULTS: Eighty subjects were enrolled and distributed into case and control groups. Males were dominant in both groups, with a mean age of older than 55 years. Most lesions were in the rectum and 45% of subjects had moderately differentiated cancer. The median serum VEGF level in the case group was higher than the control group (2,175.1 pg/mL vs. 253 pg/mL; p < 0.001). VEGF gene polymorphism -634G > C was associated with the risk of colorectal cancer (p = 0.048). GG and GC genotypes had 1.89 times higher risk of colorectal cancer compared to the CC genotype. GG genotype and G allele had the highest serum VEGF levels. CONCLUSION: There is an association between VEGF gene polymorphism -634G>C and risk of colorectal cancer in this study.

show abstract

“…Te occurrence and development of CRC is a complicated and multidimensional process, and epidemiological studies have found multiple risk factors associated with the occurrence of CRC, including various unhealthy diets and lifestyles [2]. In addition, previous genomics studies have revealed that single nucleotide polymorphisms (SNPs) in several CRC-related genes are linked to the risk and progression of CRC [3][4][5][6][7][8]. For instance, the interleukins-17A (IL-17A) rs2275913 G > A polymorphism was associated with the occurrence and severity of CRC in the Bulgarian population [6].…”

Section: Introductionmentioning

confidence: 99%

TP73-AS1 rs3737589 Polymorphism is Associated With the Clinical Stage of Colorectal Cancer

Gao

Zhang

Gao

2023

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. TP73-AS1 can promote the occurrence and development of a variety of tumors, including colorectal cancer (CRC). The current study aimed to investigate the association between a potentially functional genetic polymorphism (rs3737589 T > C) on the TP73-AS1 gene and the susceptibility and clinical stage of CRC in a Chinese Han population. Methods. The polymorphic genotyping was performed by the SNaPshot method. The real-time quantitative PCR method and the luciferase assay were used separately to explore genotype-tissue expression and the function of the genetic polymorphism. Results. A total of 576 CRC patients and 896 healthy controls were included in the current study. The rs3737589 polymorphism was not associated with CRC susceptibility but was associated with the CRC stage (CC vs. TT: OR = 0.25, 95% CI = 0.12 – 0.54, P = 0.0003 ; C vs. T: OR = 0.69, 95% CI = 0.53–0.89, P = 0.006 ; and CC vs. (TC + TT): OR = 0.26, 95% CI = 0.12–0.56, P = 0.0004 ). CRC patients carrying the rs3737589 CC genotype or C allele were less likely to have stage III/IV tumors than those carrying the rs3737589 TT genotype or T allele. The expression of TP73-AS1 was lower in CRC tissues with the rs3737589 CC genotype compared to those with the TT genotype. Bioinformatics analysis and the luciferase assay revealed that the C allele could promote the binding of miR-3166 and miR-4771 to TP73-AS1. Conclusion. The TP73-AS1 gene rs3737589 polymorphism affecting miRNAs binding is associated with the CRC stage and may serve as a biomarker for predicting CRC progression.

show abstract

The association of VEGF rs833061 and rs2010963 polymorphisms with susceptibility to colorectal cancer in an Iranian population

Cited by 7 publications

References 43 publications

The relationship between VEGF-460(T>C) polymorphism and cancer risk: A systematic review and meta-analysis based on 46 reports

The relationship between VEGF-460(T>C) polymorphism and cancer risk: A systematic review and meta-analysis based on 46 reports

Association between VEGF Gene Polymorphism -634G>C and Risk of Colorectal Cancer

TP73-AS1 rs3737589 Polymorphism is Associated With the Clinical Stage of Colorectal Cancer

Contact Info

Product

Resources

About